MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.17068

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2022

Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.

Pauwels Ans, Raymenants Karlien, Geeraerts Annelies, Boecxstaens Veerle, Masuy Imke, Broers Charlotte, Vanuytsel Tim, Tack Jan

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Proton pump inhibitors (PPI) have no effect on non-acid reflux events which can continue to provoke gastro-oesophageal reflux disease (GERD) symptoms. Baclofen, a γ-aminobutyric acid agonist, can decrease non-acid reflux but its symptomatic benefit in refractory GERD symptoms is understudied.

AIMS: To assess the efficacy of baclofen 10 mg t.i.d. vs placebo as add-on therapy in PPI-refractory GERD symptoms, in a randomised, double-blind, placebo-controlled study.

METHODS

Patients with persisting typical GERD symptoms on b.i.d. PPI therapy were randomised to 4 weeks of baclofen 10 mg or placebo t.i.d. Before and after treatment, patients underwent 24 h impedance-pH monitoring on-PPI. Throughout the study, patients filled out ReQuest diaries. Data were analysed using mixed models.

RESULTS

About 60 patients were included (age 47.5 years [range 19-73], 41f/19 m), 31 patients were randomised to baclofen. One patient withdrew consent and five in the baclofen group stopped treatment due to side effects. There was a trend towards a better response for general wellbeing in the baclofen-treated group compared to placebo (p = 0.06). When subdividing patients according to symptom association probability (SAP), only the SAP+ (n = 25) group improved significantly with baclofen (pcorr  = 0.02), and worsened with placebo (pcorr  = 0.008). The total number of reflux events decreased over time (p = 0.01), mainly due to the baclofen condition (pcorr  = 0.1). The number of reflux events with a high proximal extent dropped significantly after baclofen (pcorr  = 0.009), but not placebo.

CONCLUSION

Baclofen decreases several reflux parameters in PPI refractory GERD symptoms, but pH-impedance monitoring is necessary before treatment as only SAP+ patients experience clinical benefit after 4 weeks.

Для цитирования: Pauwels Ans, Raymenants Karlien, Geeraerts Annelies, Boecxstaens Veerle, Masuy Imke, Broers Charlotte, Vanuytsel Tim, Tack Jan. Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.. Alimentary pharmacology & therapeutics. 2022. DOI: 10.1111/apt.17068.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.